氨磺必利用于慢性精神分裂症伴糖尿病患者的疗效分析  

A self-controlled trial of Amisulpride in treatment of chronic schizophrenia patients with diabetes

作　　者：宋丽娜[1] 郭艳红[1] 石少波[1] SONG Li-na;GUO Yan-hong;SHI Shao-bo(Qingdao Mental Health Center,Shandong 266034,China)

机构地区：[1]青岛市精神卫生中心,山东青岛266034

出　　处：《中国处方药》2018年第9期13-14,共2页Journal of China Prescription Drug

摘　　要：目的探讨氨磺必利用于治疗慢性精神分裂症伴糖尿病患者的疗效。方法对30例慢性精神分裂症伴糖尿病患者进行病例自身对照研究,换用氨磺必利治疗,观察12周。用阳性与阴性症状量表(PANSS)评定临床疗效,检测空腹及餐后2小时血糖,评估氨磺必利对慢性精神分裂症的疗效及血糖的影响。结果患者应用氨磺必利12周后,精神症状好转的占23.3%,无明显变化的占76.7%。血糖水平与基线相比降低的占83.3%,其中降至正常的占63.3%,血糖水平变化不明显的占16.7%。结论氨磺必利用于治疗精神分裂症效果较好,可以减轻某些抗精神病药物引起的血糖增高。Objective Explore the effect of amisulpride on diabetes in patients with chronic schizophrenia.Methods A case-control study was given to thirty cases were identified with hyperglycemia in chronic schizophrenia patients.Changed with amisulpride for treatment,the period of observation is 12 weeks.Positive and Negative Syndrome Scale(PANSS)is used to evaluate the clinical efficacy,and testing fasting and postprandial 2 hours blood glucose.Assess the effects of amisulpride and blood sugar in chronic schizophrenia patients.Results Patients with amisulpride 12 weeks,the improvement of psychiatric symptoms accounted for 23.3%and no significant change of cases is 76.7%.Lower blood sugar accounted for 83.3%compared with baseline,which fell to the normal accounting for 63.3%,and levels of blood glucose did not change significantly accounted for 16.7%.Conclusion It’s effective for amisulpride to treatschizophrenia patients with diabetes,andmay reduce blood sugar caused by some antipsychotics.

关 键 词：氨磺必利 精神分裂症 糖尿病 

分 类 号：R749.3[医药卫生—神经病学与精神病学]